Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer

  • Authors:
    • Chang Hoon Han
    • Jae Yong Cho
    • Jong Tae Moon
    • Hyung Jung Kim
    • Se Kyu Kim
    • Dong Hwan Shin
    • Joon Chang
    • Chul Min Ahn
    • Sung Kyu Kim
    • Yoon Soo Chang
  • View Affiliations

  • Published online on: December 1, 2006     https://doi.org/10.3892/or.16.6.1205
  • Pages: 1205-1210
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Insulin receptor substrate-1 (IRS-1) is an adaptor protein for insulin-like growth factor (IGF) signaling and it is presumed associated with cancer development, progression or clinical outcome of patients harboring solid tumors. Therefore, we investigated by immunohistochemistry, the expression of IRS-1 in the tumor tissues from 94 patients who were diagnosed as stage I non-small cell lung cancer (NSCLC) and had undergone a curative lung resection. The relationships between its intratumoral expression and various clinical parameters were explored. IRS-1 is consistently expressed in the cytoplasm of intrapulmonary bronchial and bronchiolar epithelial cells comprising normal appearing adjacent lung tissues. Forty-one (43.6%) of 94 specimens showed loss of IRS-1 expression. In a subset analysis, IRS-1 was more frequently lost in stage IB than in IA tumors (50.0 vs. 22.7%, p=0.024, χ2 test), which was reflected by the facts that tumors which showed down-regulation of IRS-1 had larger area than those with IRS-1 expression (18.1 vs. 12.1 cm2, p=0.044, t-test). Down-regulation of IRS-1 is more frequently observed in squamous cell carcinoma than other cell type lung cancer (p=0.002, χ2 test) and its expression was not affected by histological grade of differentiation. Comparing pack-years (P.Y.) between groups of smokers whose tumor expressed IRS-1 and those that did not, smokers whose tumor showed loss of IRS-1 expression had higher P.Y. than those whose tumor did express IRS-1 (39.2±23.67 vs. 25.6±26.61 P.Y., p=0.034, t-test). Intratumoral expression of IRS-1 did not influence disease-free survival, disease-specific survival or overall survival of stage I NSCLC patients, whose median follow-up duration is 7.5 years (95% CI; 7.21-7.86 years). These results suggest that loss of IRS-1 might rather be an early event in NSCLC development than a prognostic factor and that it is more strongly related with squamous cell carcinoma and with smoking.

Related Articles

Journal Cover

December 2006
Volume 16 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Han CH, Cho JY, Moon JT, Kim HJ, Kim SK, Shin DH, Chang J, Ahn CM, Kim SK, Chang YS, Chang YS, et al: Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer. Oncol Rep 16: 1205-1210, 2006
APA
Han, C.H., Cho, J.Y., Moon, J.T., Kim, H.J., Kim, S.K., Shin, D.H. ... Chang, Y.S. (2006). Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer. Oncology Reports, 16, 1205-1210. https://doi.org/10.3892/or.16.6.1205
MLA
Han, C. H., Cho, J. Y., Moon, J. T., Kim, H. J., Kim, S. K., Shin, D. H., Chang, J., Ahn, C. M., Kim, S. K., Chang, Y. S."Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer". Oncology Reports 16.6 (2006): 1205-1210.
Chicago
Han, C. H., Cho, J. Y., Moon, J. T., Kim, H. J., Kim, S. K., Shin, D. H., Chang, J., Ahn, C. M., Kim, S. K., Chang, Y. S."Clinical significance of insulin receptor substrate-I down-regulation in non-small cell lung cancer". Oncology Reports 16, no. 6 (2006): 1205-1210. https://doi.org/10.3892/or.16.6.1205